FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders
The FDA approved Novartis AG's Cosentyx 150 mg to treat adults with polymyalgia rheumatica (PMR) who do not respond to or cannot tolerate corticosteroids. The approval is based on the Phase 3 REPLENISH study, which showed sustained remission rates of 40.5% for Cosentyx 150 mg compared to 20.5% for placebo. Novartis shares were down 1.07% premarket on Tuesday.
How this was made

The 30-second read
Why it matters
FDA clearance makes Cosentyx the first and only anti-IL-17 biologic approved for PMR, supported by REPLENISH Phase 3 results after a 24-week steroid taper.
Market read
A first-in-class FDA approval for a defined PMR population is a direct, tradable catalyst for Novartis’ immunology franchise.
What to watch
The article does not quantify expected sales, pricing, or uptake; traders may need to watch formulary decisions and post-approval guidance from Novartis for confirmation.
Background
PMR is an inflammatory disorder affecting older adults, where standard care relies heavily on long-term corticosteroids despite relapse risk and steroid complications.
Ticker impact
FDA approved Novartis’ Cosentyx 150 mg for polymyalgia rheumatica patients who inadequately respond to or cannot taper off corticosteroids.
Likely upward bias as markets price in incremental demand for Cosentyx in PMR and reduced reliance on long-term steroids.
The article describes a first-in-class anti-IL-17 biologic approval for a defined PMR population, backed by Phase 3 REPLENISH remission data and FDA clearance.
Market effects
Reinforces anti-IL-17 biologics as viable steroid-sparing therapies in immune-mediated inflammatory disease, potentially sharpening competitive expectations in rheumatology.
US regulatory approval can shift sentiment toward large-cap pharma with late-stage immunology pipelines.
Global PMR treatment standards may evolve as FDA-cleared data are used by clinicians and payers beyond the US.
Counterpoint
Even with approval, real-world adoption may be slower due to payer restrictions, clinician inertia, and the need to demonstrate steroid-sparing benefits versus existing options.
Key entities
- companyNovartis
Sponsor of Cosentyx, which received FDA approval for PMR in steroid-inadequate or steroid-intolerant adults.
- drugCosentyx (secukinumab)
Anti-IL-17 biologic approved at 150 mg for PMR with inadequate corticosteroid response or inability to taper.
- regulatorFDA
Approved the new indication based on REPLENISH Phase 3 data.
- clinical_trialREPLENISH trial
Phase 3 study showing higher sustained remission rates at week 52 after steroid taper.



